Bharat Dynamics (BDL) Q4 10/11 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 10/11 earnings summary
21 Oct, 2026Executive summary
Record FY2010-11 sales of ₹939.10 crore, up 50% YoY; profit after tax rose 53% to ₹51.70 crore.
A ₹14,180 crore Akash surface-to-air missile contract for the Indian Army and an order book of ~₹20,000 crore support planned growth.
Financial highlights
Sales ₹939.10 crore vs ₹627.23 crore YoY; value of production ₹910.92 crore, up 44%; value added ₹330.78 crore, up 71%.
PBT ₹79.17 crore, up 56% YoY; PAT ₹51.70 crore, up 53% YoY.
Other income was ₹143.75 crore vs ₹150.42 crore; it included ₹29.9955 crore of provisions no longer required.
Outlook and guidance
FY2011-12 sales target exceeds ₹1,300 crore, representing targeted growth of 45% over FY2010-11 actual sales.
Order book stood at ~₹20,000 crore, with further increases expected; major delivery commitments include Akash SAM and Milan-2T, Konkurs-M and Invar ATGMs.
Capacity expansion, production visibility systems and full ERP integration are intended to support higher output and delivery execution.
Latest events from Bharat Dynamics
- A ~₹19,000 crore order book supports growth after FY12 profit surged on higher other income.BDL
Q4 11/12 - Sales and PAT advanced, but working-capital demands drove operating cash flow negative.BDL
Q4 12/13 - Record FY14 growth backed by missile orders, with execution and competition risks.BDL
Q4 13/14 - Record sales, higher profits and a ₹16,357 crore order book underpin expansion plans.BDL
Q4 14/15 - Record sales and a ₹13,721 crore order book fuel growth, amid demanding delivery commitments.BDL
Q4 15/16 - Record sales and a ₹11,170 crore order book, despite lower FY17 profits.BDL
Q4 16/17 - Record turnover and operating gains, offset by lower interest income and delivery risks.BDL
Q4 17/18 - Lower FY19 sales, stronger operating margins and a ₹7,258 crore order book define the outlook.BDL
Q4 18/19 - PAT rose 26.48% as a ₹7,413 crore order book anchored outlook amid COVID risks.BDL
Q4 19/20